1. Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, et al. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34(6):1495-502.

  2. Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The “hit hard and hit early” approach to the treatment of chronic myeloid leukemia: Implications of the updated national comprehensive cancer network clinical practice guidelines for routine practice. Clinical Advances in Hematology and Oncology. [Article]. 2013;11(7):421-32.

  3. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403-12.

  4. Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497-500.

  5. Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648-71.

  6. Rabian F, Lengline E, Rea D. Towards a personalized treatment of patients with chronic myeloid leukemia. Current Hematologic Malignancy Reports. 2019;14(6):492-500.

  7. McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, et al. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current medical research and opinion. 2016;32(2):289-99.

  8. Atallah E, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Patwardhan P, editors. Real-World Treatment Pat-terns, Healthcare Resource Utilization and Associated Costs among Patients with CML in Later Lines of Therapy. American Society of Hematology; 2020.

  9. Kropf P, Barnes G, Tang B, Pathak A, Issa JP. Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Leukemia & lymphoma. 2016;57(4):935-41.

  10. De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, et al. The impact of chronic myeloid leukemia on employment: the French prospective study. Ann Hematol. 2019;98(3):615-23.

  11. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood. 2021.

  12. Rea D, Mauro MJ, Hochhaus A, Boquimpani C, Lomaia E, Voloshin S, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after≥ 2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. American Society of Clinical Oncology; 2022.

  13. Rea D, Hochhaus A, Mauro MJ, Minami Y, . Efficacy And Safety Results From Ascembl, A Phase 3 Study Of Asciminib Vs Bosutinib In Patients With Chronic Myeloid Leukemia In Chronic Phase After ≥2 Prior Tyrosine Kinase Inhibitors: Wk 96 Update. European Hematology Association; 2022.

  14. Novartis. Clinical Study Report: A Phase III, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors. Key secondary endpointanalysis at 96 weeks. (Data on file). 2022.

  15. Último prospecto aprobado por ANMAT

  16. NCCN. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia Version 3.2022. National Comprehensive
    Cancer Network, Inc.; 2022 [updated 27 January 2021; cited 2022 18 April 2022]; Available from: https://www.nccn.org/professionals

  17. Hehlmann R. Chronic Myeloid Leukemia in 2020. Hemasphere. 2020 Sep 30;4(5):e468.

  18. Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leu-kemia. 2023;37(3):617-26.